FDA has approved secukinumab (Cosentyx, Novartis) for the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis.
Formulary Watch
Latest News
All News
Advertisement
It is young white males who are dying from drug overdoses in the U.S., according to a New York Times analysis of death certificates.
Abbott's Compounding Pharmacy in Berkeley, Calif., is voluntarily recalling all unexpired lots of sterile compounded products because of lack of sterility assurance.
FDA has approved an expanded age indication for Hib vaccine (Hiberix, GlaxoSmithKine).
There is some good news for heart failure patients’ life expectancy, in a recent study published in the New England Journal of Medicine.
FDA advisers recommended approval of the first long-acting, subdermal buprenorphine implant (Probuphine, Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals) for the maintenance treatment of opioid addiction.
Pharmaceutical companies are battling state legislation that would require state programs such as Medicaid to pay no more than other Federal government programs for drugs.
After a death and a hospitalized patient, FDA is cautioning that differences in dosing regimens between the 2 oral formulations of Merck’s antifungal drug Noxafil (posaconazole) have resulted in dosing errors.
Gilead Sciences, which already makes the leading hepatitis C drugs Harvoni and Sovaldi, recently received priority review from FDA for a new Hepatitis C combination drug.
Advertisement
Amicable resolution between FDA and Pacira Pharmaceuticals, Inc., which reaffirms the broad indication for Exparel (bupivacaine liposome injectable suspension).
Hospital pharmacies need to check their supplies of norepinephrine after PharMEDium Services in Lake Forest, Ill., voluntarily recalled several lots of Norepinephrine Bitartrate. The product is used to control blood pressure in certain acute hypotensive states.
In late December, FDA approved AstraZeneca’s Zurampic (lesinurad) 200-mg tablets in combination with a xanthine oxidase inhibitor (XOI) for high levels of uric acid in the blood (hyperuricemia) associated with gout.
FDA approved expanded age indication for Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil 9, Merck) in males.
The FDA recently granted orphan drug approval to Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.
In the latest controversy over drug pricing, an organization said that the price of GlaxoSmithKline’s Nucala (mepolizumab), an injectable indicated for severe asthma patients with eosinophilic inflammation, is far over-priced.
Sales of Merck’s Keytruda (pembrolizumab) are expected to increase, after FDA approved the drug for first-line treatment of melanoma.
FDA approved insulin glargine injection (Basaglar, Eli Lilly) to improve glycemic control in patients with diabetes mellitus.
Pete Mulliner, an IPF patient and ambassador for the Pulmonary Fibrosis Foundation, discusses how he believes physicians should treat patients who have been recently diagnosed with IPF.
FDA approved Bridion (sugammadex) injection today – after a long wait by Merck & Co. – to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, used during certain types of surgery.
Valeant Pharmaceuticals just entered into a new fulfillment agreement with Walgreens and says it will reduce prices of its branded prescription-based dermatological and ophthalmological products such as Jublia by 10 percent.
FDA granted accelerated approval to Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Hospital stays were shorter for patients treated with Xarelto (rivaroxaban) in a new study, compared to those receiving standard anticoagulants.
Wellstat Therapeutics Corporation said that its Vistogard, just approved by FDA as the first and only antidote for emergency treatment of adult and pediatric patients following an overdose of the chemotherapy, will be available on the U.S. market soon.
Boehringer Ingelheim recently began a clinical trial to assess the safety and tolerability of adding on pirfenidone to Ofev (nintedanib) for idiopathic pulmonary fibrosis patients.
FDA is warning about ketoacidosis and urinary tract infections associated with the relatively new class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Invokana and Jardiance.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
HS patients on biosimilar adalimumab lose response faster than those on the original drug
3
New drug class shows promise for geographic atrophy
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5
